Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Valneva SE VALN
$12.08
-$0.43 (-3.59%)
На 18:04, 12 мая 2023
Ранг: 1
Ключевые показатели
-
Marketcap
846613376.00000000
-
week52high
33.76
-
week52low
9.07
-
Revenue
361303000
-
P/E TTM
-12
-
Beta
0.98435100
-
EPS
-2.81000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 04:00
Описание компании
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 22 авг 2022 г. |
| HC Wainwright & Co. | Buy | 03 авг 2022 г. | |
| Jefferies | Buy | 01 июн 2021 г. | |
| Goldman Sachs | Buy | 01 июн 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why
Zacks Investment Research
16 янв 2023 г. в 12:02
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
What Makes Valneva SE Sponsored ADR (VALN) a New Buy Stock
Zacks Investment Research
03 янв 2023 г. в 13:32
Valneva SE Sponsored ADR (VALN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab
Zacks Investment Research
06 дек 2022 г. в 09:47
Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.
Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data
Zacks Investment Research
02 дек 2022 г. в 12:02
Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.
Will A Pfizer-Partnered Vaccine Help Valneva Stock Buck Its Recent Downtrend?
Investors Business Daily
01 дек 2022 г. в 10:42
Valneva stock rose Thursday after it said volunteers who received its Pfizer-partnered Lyme disease shot still had antibodies after six months. The post Will A Pfizer-Partnered Vaccine Help Valneva Stock Buck Its Recent Downtrend?